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 Chlorpyrifos is a commonly utilized organophosphate pesticide, and as recently as 2007, was the most 
commonly used insecticide within the United States. Its ubiquity is concerning given its potential to cause 
developmental issues among younger organisms and its association with neurodegenerative conditions like 
Parkinson’s Disease. Pathways by which these issues arise are unclear since these effects can occur in absence of 
acetylcholinesterase inhibition. To this end, experiments utilizing Caenorhabditis elegans as a model were 
performed. The organism is useful as a model for several reasons, of which are its rapid maturation, its ease of 
maintenance, and its transparent body that allows examination of intact bodily systems. C. elegans also possesses a 
fully characterized neuronal lineage with a complete neural wiring diagram, and several conserved neurotransmitter 
systems. 
 The primary purpose of this research was to determine if chlorpyrifos would have an impact on the 
behavior, morphology, or nervous system of C. elegans at selected concentrations, ranging from low levels 
considered generally safe to high levels with noted lethal impacts on C. elegans. Populations were grown on media 
containing chlorpyrifos during larval stages and then transferred to media without chlorpyrifos for 24 hours to 
separate developmental impacts of chlorpyrifos from its active effects. Analysis of chlorpyrifos-exposed C. elegans 
produced some notable results. Video analysis revealed that worms exposed to high chlorpyrifos concentrations had 
decrease in body length and width. Exposure to high concentrations of chlorpyrifos showed increasing germline 
apoptosis over control groups. Pharyngeal pumping assays showed paralysis at high concentrations, and no paralysis 
at low concentrations. Finally, an assessment of C. elegans dopaminergic neurons indicated neuron loss at both low 
and high developmental exposure. These results show a deleterious impact at high concentrations, with worms 
showing developmental delays and stunted growth. The compound seems capable of impacting bodily systems 
outside of the nervous system, as seen in the germline apoptosis assay. Concentrations tested have the desired 
impacts, with high chlorpyrifos exposure groups showing paralysis and low dose groups showing no paralysis. Most 
interestingly, the pesticide appears to cause dopaminergic neuron degradation at low concentrations, providing a link 
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 Chlorpyrifos, trade names Dursban and Lorsban, is an organophosphate compound 
utilized as a broad-spectrum pesticide, capable of killing a variety of insects and arachnids 
including pest larva, grubs, cockroaches, flea beetles, flies, termites, ants, and lice.1 It was 
introduced for use by Dow Chemical in 1965, and since then has gone on to become one of the 
most commonly utilized pesticides within the United States and the world.2 It is registered for 
use in over 100 different countries and as recently as 2007, was the most commonly utilized 
insecticide within the United States with between 7 and 9 million pounds of the substance being 
used.2,3 It’s most commonly used as an agricultural insecticide, and it is mostly used on cotton, 
corn, almond trees, and various fruit trees including apples, bananas, and oranges.4 Chlorpyrifos 
also finds non-agricultural use as a pesticide on golf courses, lawns, sporting fields, and in green 
houses. Finally, it often finds use as a non-structural wood treatment to prevent pest damage.5 
Environmental Persistence 
 In the 1970s, the United States shifted away from organochlorine insecticides, of which 
there were concerns of toxicity to fish and wildlife along with a potential for bioaccumulation, 
and towards organophosphate insecticide compounds.6 Organophosphate compounds tend to 
degrade more readily; chlorpyrifos in particular has a soil half-life between 10 and 120 days 
depending on soil conditions.7 Furthermore, the compound binds tightly to soil, making 
contamination of water supplies surrounding application sites difficult without significant soil 
erosion.8  
 The primary ways in which chlorpyrifos finds its way into water sources are through 
spray drift during application of the pesticide or through instances of significant soil erosion.9 
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Depending on the form of chlorpyrifos used (powder or emulsifiable concentrate versus 
controlled release formations), the concentrations within water can achieve a rapid high or a low-
level persistence.9 Once in water, chlorpyrifos will normally bind to sediment and organic matter 
along the bottom of a body of water. From here, slow desorption from sediment can lead to a low 
(ppb) concentration of chlorpyrifos in water for long periods of time. At a neutral pH at 25ºC, 
chlorpyrifos has a half-life between 35 and 78 days.10 Chlorpyrifos that doesn’t bind to sediment 
will usually leave water supplies through volatilization. Within an outdoor atmosphere, 
chlorpyrifos has a half-life of approximately three days; indoors it can persist for months.11 
 Once chlorpyrifos is in the environment, it tends to degrade relatively quickly compared 
to other compounds. However, residues of chlorpyrifos can remain on surfaces for much longer 
periods of time. These residues can be found on fruits and vegetables consumed by people, 
leading to exposure to the pesticide.11 
Exposure Routes and Exposed Populations 
 Populations can come into contact with and absorb chlorpyrifos in a few different ways. 
The chemical can be absorbed through dermal contact, through compound ingestion, or through 
inhalation of evaporated chlorpyrifos. Among these routes, dermal contact absorption is the most 
minor. Over a 24-hour period, only 1-2% of an applied dose appears to be absorbed from the 
skin, though this absorption can be as high as 11-20% depending on the formulation in which 
chlorpyrifos is found.12,13 Outside of groups directly applying chlorpyrifos to surfaces or crops or 
those coming into contact with recently treated surfaces however, it is unlikely for a person to 
absorb a significant quantity of chlorpyrifos in this way. 
 While direct studies on absorption of inhaled chlorpyrifos have yet to be performed, it’s 
generally assumed that the compound is well absorbed through the lungs.14 Studies examining 
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workers involved in chlorpyrifos production, where airborne concentrations of the compound 
ranged from 10 to 1100μg/m3, showed reductions in butyrlcholinesterase levels 19-32% lower 
than unexposed matched controls.15 It should however be noted that these levels of exposure are 
not expected for a general population. Even among counties with heavy agricultural use of 
chlorpyrifos, outdoor air concentrations of chlorpyrifos were on average 0.033μg/m3.16  
 Presently, the most common way people are exposed to chlorpyrifos is through 
consumption of the compound present as a residue on fruits, vegetables, and nuts. When 
consumed, chlorpyrifos is thought to be at least 70% bioavailable.12 It’s estimated that the 
average adult, toddler, and infant in the United States consumes roughly 0.005, 0.014, and 
0.009μg/kg-bw per day, respectively.11 These estimates are expected to be higher among 
individuals that consume a greater amount of fruits and vegetables. Aside from residues, 
chlorpyrifos can also be consumed as a component of dust within the environment, though 
restrictions on indoor use of the chemical likely have limited this.11 
 Overall, it’s expected that the general population is exposed to chlorpyrifos 
predominantly through food consumption, while populations that work directly with chlorpyrifos 
(processors, applicators, etc.) along with those associated with these populations will absorb the 
compound through all exposure routes, leading to potential cumulative effect. The most heavily 
exposed populations are likely to be those working or living in rural or agricultural areas. There 
is a correlation between agricultural use of an area and increasing airborne concentrations of 
chlorpyrifos along with evidence that those working with the compound can carry it into their 





 The primary use of chlorpyrifos, and indeed all organophosphates, is as an agricultural 
pesticide. The compound has a negative impact on multiple bodily systems.18 However, it’s 
predominant, and most fully understood, toxic activity is the inhibition of acetylcholinesterase. 
Chlorpyrifos is a phosphorothioate, meaning it possesses a P=S bond.  These phosphorothioate 
compounds are activated within the body by cytochrome P450 (CYP)-mediated 
monooxygenases, leading to either a desulfuration reaction or a dearylation reaction (see figure 
1).19 
 While dearylation results in conversion of chlorpyrifos to less toxic substances, 
desulfuration produces a much more acutely toxic compound, chlorpyrifos-oxon. The 
oxygenated form of chlorpyrifos is capable of permanently inhibiting acetylcholinesterase.20 This 
inhibition results in an accumulation of acetylcholine between neurons, which results in stronger, 
longer lasting signals to receiving neurons until new acetylcholinesterase can be produced by the 
body. Short term exposure to low concentrations can cause dizziness, fatigue, runny nose or 
eyes, salivation, nausea, intestinal discomfort, sweating, and changes in heart rate. Exposure to 
higher concentrations can cause seizures, paralysis, loss of consciousness, and death.21   
Unknown Toxicology 
 While the above mentioned mechanism is the primary toxicological pathway for 
chlorpyrifos, there is evidence to suggest it may have other developmental neurotoxic effects not 
directly attributable to this action. Introduction of chlorpyrifos directly into the brains of neonatal 
rodents, bypassing desulfuration metabolism, has resulted in disruption of normal brain cell 
replication.22 In fact, chlorpyrifos, along with other organophosphates, can disrupt developmental 
neuronal proliferation, differentiation, axon, synapse and glial cell genesis, and neural 
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apoptosis.23,24 In vitro studies have also provided evidence that chlorpyrifos-oxon may impact 
neurodevelopment without inhibition of acetylcholinesterase, with potential targets being cell 
signaling molecules or cytoskeletal proteins.20  
Chlorpyrifos and Parkinson’s Disease 
 Parkinson’s Disease is a neurodegenerative disorder resulting primarily from the loss of 
dopaminergic neurons in the substantia nigra of the brain.25 The disease is characterized by 
shaking or trembling along limbs and the face, stiffness of limbs and torso, slowing of 
movement, and gradually deteriorating balance and coordination.26 These symptoms make 
general movement difficult, and the progressive nature of the disease means the effects of the 
disease become worse over time. Additional disease symptoms include difficulty in chewing or 
swallowing, difficulty with speech, urinary and gastrointestinal difficulties, skin problems, and 
sleep disruption. Depression and other emotional changes are also common among those affected 
by PD.27 
 To date, Parkinson’s Disease is one of the most common neurodegenerative disorders in 
the world, second only to Alzheimer’s Disease; it affects roughly 7 million people across the 
world and 1 million within the United States.28 It is more common among the aging and elderly, 
occurring in 1% of those over 60 and 4% of those over 80, though 5-10% of cases are considered 
“young-onset” and begin between the ages of 20-50.29 Roughly 0.3% of the population within 
industrialized countries is estimated to be afflicted by PD, and it’s expected that between 8 to 18 
people out of every 100,000 will develop the disease each year.27 
 With the exception of known genetic factors leading to direct disease manifestation, the 
exact causes of Parkinson’s Disease are unknown. However, there is a positive correlation 
between pesticide exposure and risk of Parkinson’s Disease development.30 Particular interest 
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has been given to neurotoxic pesticides, including organophosphate pesticides like 
Chlorpyrifos.31 In fact, several epidemiological population studies have found an increased risk 
of Parkinson’s Disease associated with exposure to chlorpyrifos.30 Current studies however do 
not elucidate a definitive link between exposure and disease development, leaving open the 
possibility of confounding elements falsely correlating the two phenomena. 
 Since dopaminergic neuron loss is a characterizing feature of Parkinson’s disease, and 
chlorpyrifos exposure can increase risk of disease development, a portion of this study is 
dedicated to determining if chlorpyrifos can trigger or enhance degradation of dopaminergic 
neurons within C. elegans. Dopaminergic neurons in C. elegans respond to mechanical 
stimulation from bacteria within their environments, facilitating a basal slowing response that 
decreases their movement speed in the presence of bacterial food sources.32,33 Utilizing UA44-
strain C. elegans, it is possible to directly observe the impact of chlorpyrifos on these neurons 
and potentially directly link exposure to disease development and progression. 
Cause for Concern 
Currently, non-occupational exposure to chlorpyrifos should be low enough to avoid 
adverse developmental effects due to acetylcholinesterase inhibition. However, there is evidence 
that the compound may impact development through different routes at lower concentrations, 
which may be cause for alarm given the compound’s ubiquity.34 Studies with rats have shown 
that exposure to chlorpyrifos during neonatal and postnatal life stages can cause developmental 
delays in coordination and reflexes as well as locomotion.35,36 Evidence of developmental issues 
can also be found in humans. A study evaluating the relationship between chlorpyrifos levels in 
umbilical cord plasma and behavioral development noted that behavioral disorders were 
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significantly more likely to occur in toddlers whose umbilical plasma chlorpyrifos concentrations 
were above 6.17pg/g than in those toddlers who were below this threshold.37 
New animal models may help elucidate secondary toxicological routes and actions for 
chlorpyrifos and establish concentrations at which neurodevelopmental or neurodegenerative 
impairments may occur. Preferable models should possess a well-documented nervous system 
















II. Significance  
Unknowns of Chlorpyrifos 
 While the primary route of chlorpyrifos toxicity is known and accounted for when 
establishing limits on exposure, potential secondary routes of toxicity aren’t well characterized, 
with only a few hypothetical routes identified in vitro. Exposure of neuronal cells to chlorpyrifos 
concentrations 0.1-1nM showed decreases in axon length, and in vitro treatment of rat cortical 
neurons to chlorpyrifos and chlorpyrifos-oxon caused increased phosphorylation of CREB, a 
gene that plays a major role in gene expression.34 These effects are shown at concentrations 
below those at which chlorpyrifos inhibits acetylcholinesterase. Perhaps more troubling, analysis 
of effects resulting from these concentrations are limited. With some evidence linking neural 
disorders in young children with fetal and early infancy chlorpyrifos exposure,37 coupled with 
the wide spread use of chlorpyrifos as an insecticide,38,3 it is a matter of urgency that the 
unknown toxicology of chlorpyrifos be described as fully as possible. 
Validation of C. elegans Model 
 C. elegans provides several advantages as an animal model, particularly in regards to 
analyzing neurodevelopmental impacts of toxicant exposure. With a fully characterized and 
simple nervous possessing several neurotransmitter systems shared in common with 
vertebrates,39 C. elegans could potentially allow one to examine how chlorpyrifos affects the 
developing nervous system in full and in detail. Given its small transparent body, these effects 
can even be viewed within living organisms. Its rapid life cycle is also ideal for examining 
developmental effects in general, given the relatively short time frame between larval exposure 
and analysis of adults. 
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 The greatest challenge to C. elegans as a model however is its taxonomic distance from 
humans when compared to other mammalian model organisms. As of yet, there is not enough 
certainty that C. elegans will react to chlorpyrifos in ways comparable to a higher eukaryote. 
Without evidence of comparability, the total effects of chlorpyrifos on C. elegans may be less 
applicable when considering its effects on humans. The necessity of this work thus lies in 
supporting or refuting C. elegans as a model chlorpyrifos toxicity. 
 Thus, analysis of behavior, and the search for signs of developmental impairment, is 
critical for establishing similarity between C. elegans and other model organisms that have 
helped elucidate secondary toxic activities for chlorpyrifos thus far. Assuming this point of 
similarity is established, more detailed research can be conducted to examine the effects of 
chlorpyrifos on C. elegans, taking full advantage of all the aspects of the C. elegans model. 
Elucidation of Chlorpyrifos-Parkinson’s Disease Connection 
 One primary focus of this research is determining if chlorpyrifos exposure can cause 
symptoms associated with Parkinson’s Disease in absence of confounding factors seen in larger 
population-based studies. The primary symptoms being examined are abnormalities in C. 
elegans movement and coordination, though the more direct symptom being observed is 
degradation of dopaminergic neurons, which is the cause of most primary symptoms of 
Parkinson’s Disease. 
 A related focus is determining at what concentrations chlorpyrifos causes or enhances 
dopaminergic neuron loss. Will dopaminergic neurons only show damage at the highest levels of 
exposure, levels which should already be mitigated by existing law and regulation, or can 
damage occur at lower concentrations that might otherwise be considered innocuous? Assuming 
lower concentrations are found harmful, guidelines for chronic exposure may need review. 
 
 
III. Hypothesis and Specific Objectives 
Hypothesis 
 It was expected at the start of this experiment that chlorpyrifos would have a range of 
negative effects on C. elegans due to its neurotoxic nature. At high chlorpyrifos exposure, it was 
hypothesized that body size would be reduced, movement speed would decrease, and that 
germline cell apoptosis would increase. Since chlorpyrifos is known to cause paralysis at high 
doses, it was expected that active exposure to the compound would inhibit C. elegans pharyngeal 
pumping. Finally, exposure to chlorpyrifos was expected to cause an increase in head 
dopaminergic neuron degeneration within C. elegans. Each of these outcomes was expected to a 
far lesser degree within low chlorpyrifos exposure groups, with the exception of pharyngeal 
pumping since chlorpyrifos levels in low dose groups weren’t expected to reach a threshold 
where muscle paralysis would occur. 
 At the outset of this experiment, it was expected that C. elegans would display behavioral 
patterns comparable to reactions shown by rodents exposed to chlorpyrifos during early 
development. Exposure to chlorpyrifos was expected to inhibit C. elegans movement and 
coordination, as visualized through movement speed decrease along with changes in body 
wavelength and amplitude. It was assumed that decreases in worm speed would be dependent on 
dose, with greater decreases observed with increasing dose. 
Assuming that movement and feeding are impaired due to developmental chlorpyrifos 
exposure, it was also assumed that increased chlorpyrifos exposure might result in stunted 
growth. It was hypothesized that worm body length and width would decrease upon exposure to 
chlorpyrifos and that the decrease would be greater in heavily exposed groups. 
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 Though chlorpyrifos is not a known genotoxin, environmental stressors have been noted 
to induce germline apoptosis within C. elegans.40 It was thus expected that chlorpyrifos would 
cause some degree of stress and result in a greater count of apoptotic germline cells, identifying 
the chemical as a stressing factor. The count of apoptotic cells was expected to increase with 
exposure to greater chlorpyrifos concentrations. 
To see if C. elegans feeding was inhibited in any way due to exposure, which would 
possibly be a contributing stress factor resulting in previous stress assays like the germline 
apoptosis assay, a pharyngeal pumping assay was performed, with the assumption that pumping 
rate would be mildly inhibited at low doses and noticeably decreased with high doses. 
 Given the links between organophosphate pesticide exposure and Parkinson’s disease 
development, and knowing that a key sign of Parkinson’s disease is dopaminergic neuron loss, it 
was expected that exposure to chlorpyrifos would result in loss of C. elegans dopaminergic head 
neurons. This loss was expected to be minor in low dose groups and more pronounced in high 
dose groups. There was no expectation that exposure would show trends among a single class of 
head dopaminergic neuron, for example causing more loss among ADE neurons than CEP 
neurons or vice versa. 
Research Objectives 
 One of the primary objectives of this research is to identify what, if any, morphological 
and locomotive changes occur when C. elegans is exposed to chlorpyrifos during development. 
Lethal concentrations of chlorpyrifos in C. elegans have been determined previously. The 
compound has a 24hr LC10 of 0.298mg/L and a 24hr LC90 of 3.135mg/L within liquid media.
41 
However, behavioral and physiological effects of chlorpyrifos exposure haven’t been reported in 
great detail. WormLab analysis of behavioral videos should reveal and quantify what, if any, 
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changes occur in C. elegans behavior, movement, and body size. If changes can be observed, 
especially at lower test concentrations, this will provide evidence of chlorpyrifos toxicology 
beyond its acetylcholinesterase inhibition.  
 A secondary goal of research is to see if chlorpyrifos is capable of eliciting a deleterious 
response outside of the nervous system; apoptosis assays can answer this and may provide some 
evidence as to the cause of any observed changes among exposed worms in appearance, 
movement, size, or development. Apoptosis pathways in C. elegans encompass several genes, 
with groups of genes associated with apoptosis caused by genetic damage, starvation, and 
oxidative, osmotic, and heat stress.40 Positive identification of germline cell apoptosis is thus an 
important step in identifying the effects chlorpyrifos has C. elegans. It is also important to see 
what chlorpyrifos concentrations can induce apoptosis. 
 Two important goals of this research are to begin identifying what factors may contribute 
to any observed increase in apoptosis and under what conditions chlorpyrifos exhibits its typical 
paralytic action. Examining pharyngeal pumping rate allows observation of how efficiently a 
worm feed, and a decreased rate might indicate starvation. However, if no decrease in 
pharyngeal pumping rate is observed at concentrations where other instances of stress were 
recorded, that might indicate multiple potential stressors arising from chlorpyrifos exposure. 
 A final goal of this research is to further elucidate a link between Parkinson’s Disease 
and chlorpyrifos exposure by seeing if the compound can contribute to dopaminergic neuron loss 
in the C. elegans model. Within rat models, neonatal exposure to chlorpyrifos resulted in 
reductions in dopaminergic neurons in the substantia nigra.42 Within C. elegans, could 
chlorpyrifos trigger similar neuron loss? This experiment attempts to answer this question and 
attempts to the link the neurodegenerative disorder and compound more definitively. 
 
 
IV. Experimental Design 
Model Organism-C. Elegans 
 As a model for toxicity, Caenorhabditis elegans has several advantageous qualities. It 
possesses a rapid rate of maturation, growing from fertilized egg to reproducing adult in three 
days. The small, 1mm round worm can also reproduce prolifically, with a single hermaphrodite 
individual being capable of laying 300 to 350 eggs all while being grown and sustained on a petri 
dish seeded with E. coli.43 These factors mean that large populations of the round worm are not 
difficult to produce and subject to environmental treatments, and utilizing a larger number of test 
subjects adds statistical power to results obtained. Additionally, the rapid maturation of C. 
elegans means that the effects of developmental exposure can be observed within a relatively 
short time frame; within three days, the effect of larval chlorpyrifos exposure can be measured 
within an adult worm population. 
 C. elegans also has multiple features that make it a useful model for in vivo neurotoxicity 
studies. It possesses 302 neurons with 118 characterized neuronal subtypes.44 So far, it is the only 
organism to have the entire structure of its nervous system mapped out.45 This means it is 
theoretically possible to examine the exact effects of a toxicant at a complete anatomical level 
within C. elegans. Additionally, it also shares cholinergic, γ-aminobutyric acid, (GABA)ergic, 
glutamergic, dopaminergic, and serotonergic neurotransmitter systems with vertebrates.39 As a 
model for Parkinson’s disease in humans, C. elegans is remarkably useful; all major proteins 
with mutations linked to Parkinson’s disease are conserved in C. elegans, with the exception of 
α-synuclein.46  
 However, if C. elegans is to be a useful model for human toxicology, there must be 
evidence that it reacts to toxic compounds in ways comparable to mammals. In regards to 
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organophosphate pesticides at least, there are indications that C. elegans responds to the 
chemicals similarly to higher order eukaryotes. Research found strong correlations in the rank 
order of organophosphate toxicity between C. elegans and rodents. Behavioral toxicity tests with 
C. elegans ordered a group of 15 organophosphate pesticides by toxic effect and found these 
rankings statistically consistent with the rankings of the compounds in rats and mice.47 Given 
these similarities, it is not implausible to use C. elegans as a model for developmental toxicity 
concerning Chlorpyrifos. 
 In summary, C. elegans offers easily maintained, proliferative, and manageable 
populations upon which we can test the effects of chlorpyrifos. The round worm avoids the costs 
and time investments associated with higher eukaryotes while allowing the observation of a 
greater number of organisms. The simplistic nervous system of C. elegans provides a 
compromise between in vitro studies on neural cells, which cannot observe the responses of cells 
within living systems, and in vivo studies on more complex eukaryotes, whose nervous systems 
cannot be analyzed in full detail. Furthermore, several components of the C. elegans nervous 
system are conserved among higher eukaryotes, including humans, making observations based 
on them applicable to human medical research. Finally, there is evidence that C. elegans reacts to 
organophosphate compounds in a manner comparable to mammals, which potentially gives 
direction to future experimentation involving chlorpyrifos in other animal models. 
Strains Utilized 
 Three different strains were used within the proposed experiments. For the majority of 
experiments, N2 strain C. elegans were the model organism of choice. This is a common 
laboratory strain of wild type C. elegans; most protocols for culturing and analyzing C. elegans 
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are designed with the N2 strain in mind. Video analysis and pharyngeal pumping assays were 
performed utilizing this strain.  
 The MD701 (Plim-7::ced-1::gfp; lin-15(+)) transgenic strain of C. elegans was utilized 
for studies of adult worm germline cell apoptosis. The strain possesses a CED-1:GFP marker 
which identifies cell corpses within the worm germline that are being engulfed by neighboring 
cells. This allows for the identification and quantification of apoptotic cells in still living C. 
elegans. 
The C. elegans strain UA44 (baIn11; Pdat-1::α-syn, Pdat-1::gfp) is used as a model for 
Parkinson’s Disease.48 Under control of the dat-1 (sodium-dependent dopamine transporter) 
promoter, the strain produces human α-synuclein along with GFP. Transgenic α-synuclein 
production supplements worm neurons with the single Parkinson’s Disease associated protein 
not present in C. elegans and GFP production allows for direct visualization of C. elegans head 
dopaminergic neurons. This strain was utilized for dopaminergic neuron assessment. 
Chlorpyrifos Treatment 
 C. elegans were exposed to chlorpyrifos through the media upon which they are grown 
and sustained. Nematode growth media was prepared following the methods covered in 
Maintenance of C. elegans.49 There were slight modifications however to ensure that 
chlorpyrifos adequately dissolved within the media. Solutions of chlorpyrifos were prepared 
within DMSO to create a stock, which was then mixed with the media mixture (replacing added 
water) in order to create medias with varying ‘environmental concentrations’ of chlorpyrifos. To 
minimize effects of DMSO on the study organisms, concentrations of the substance in media did 
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not exceed 0.1%. To control for these effects, media containing 0.1% DMSO without dissolved 
chlorpyrifos was used to grow control group C. elegans. 
 Medias were prepared for two test concentrations along with the 0µg/L control media. 
The lowest concentration tested will be 1µg/L, which is an established environmentally 
acceptable concentration.50 The second observed concentration was 3mg/L which is the LC90 for 
C. elegans in liquid media.41 Current LC values within solid media are unknown. These 
concentrations range from those that are theorized to have no effect or negligible effects on 
humans, to those of which there is experimental evidence for lethality in C. elegans. Testing at 
lower concentrations has the potential to either validate or challenge current measures of 
guidance concerning chlorpyrifos, while testing at the higher concentration should produce a 
measureable effect on C. elegans, allowing a starting point for future studies of chlorpyrifos 
action in this and other model organisms. 
Exposure Period 
 C. elegans populations were grown on treatment or control media during their L1 to L4 
larval stages, a period that should simulate persistent exposure to chlorpyrifos during a childhood 
developmental period in other organisms. To ensure all organisms in treatment groups are within 
the same life stage, a synchronization procedure was performed. The procedure used for 
synchronization was taken from Porta-de-la-Riva et al. (2012) with minor modifications.51 
Briefly, C. elegans worms at varying points of development are washed off of their media and 
into a 15mL tube using M9 buffer. The solution in the tube is centrifuged at 2000RPM for 2 
minutes to produce a worm pellet at the bottom of the tube. The supernatant of the tube is 
discarded and the worm pellet is washed with 5mLs of M9 buffer. It then undergoes repeated 
cycles of centrifugation and washing as stated until the observed discarded supernatant is clear. 
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At this point, 5mLs of synchronization solution (a mixture of 3.5mL water, 1mL bleach and 0.5 
mL NaOH solution) is added to the tube and the tube is shaken to disturb the worm pellet. The 
synchronization solution, after 5 to 8 minutes of vigorous mixing, kills all worms and worm 
larvae while leaving worm eggs unharmed. The solution is then centrifuged at 2000RPM for 2 
minutes to create an egg pellet, and the synchronization solution supernatant is removed and 
replaced with 5mLs of M9 buffer. The dispersed eggs undergo repeated cycles of centrifugation, 
supernatant removal and replacement at least four times in total. These wash cycles ensure 
removal of any remaining synchronization solution that may kill or impact eggs. 
 At this point, there are C. elegans eggs suspended within M9 buffer containing no food 
supply for any hatching larva. The solution is placed on a shaker in a 20ºC incubator for 20 
hours, which is sufficient time for eggs in solution to develop into L1 larva. Because there is no 
food for the larva to feed on within the solution, they are arrested at this state. The worm larva 
are then be transferred onto appropriate treatment plates seeded with OP50 E. coli, where they 
are grown until worms are in late L4 state in a 20ºC incubator. At this point, they are transferred 
to non-treatment media to grow until they are at the appropriate life stage for experimentation. 
 The procedure for transfer to treatment-free media is as follows. Worms are washed from 
treatment plates and deposited into microcentrifuge tubes for rounds of centrifugation, 
supernatant removal, and washing with M9 buffer to remove chlorpyrifos or other potential 
contaminants from the worms. The worms are deposited on treatment-free nematode growth 
media seeded with OP50 strain E. coli. Worms are allowed to grow to full egg-laying adulthood 
from the young adult stage in absence of chlorpyrifos. The treatment free growth period is an 
effort to separate active effects of the chlorpyrifos within organisms from developmental effects 
the experiments are attempting to note and quantify. The exception to this free growth period are 
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the pharyngeal pumping assays, which had the goal of observing the active effects of 
chlorpyrifos on pharyngeal pumping rate. 
WormLab 
 After completion of the above detailed exposure procedure, worms were transferred to 
nematode growth media plates seeded with OP50 E. coli. After a 30-minute acclimation period 
on the new media, videos were taken of each treatment group and the control group. Videos 
focused on individual worms and were roughly 30 seconds in length. These videos were 
analyzed via Wormlab software, which tracks all worms within a treatment group and measures 
track lengths covered by worms, worm wavelength, worm amplitude and bending, angle, speed 
of movement, and instances of omega bend behaviors. From data provided by WormLab video 
analysis, average forward and reverse movement speeds and distances covered were determined. 
Data provided was also used to track instances of reversals and proportion of time spent in 
reversal. Differences in behavior and morphology between treatment groups and the control 
group were interpreted for signs of effects from chlorpyrifos. 
WormLab software was also utilized to quantify morphological differences between 
worm populations exposed to varying levels of chlorpyrifos during development. Worm length, 
width, and area were accounted for to determine physical effects of exposure. 
Pharyngeal Pumping Assay 
Synchronized N2-strain C. elegans were plated in triplicate onto 0.05% DMSO control 
NGM, 1ug/L Chlorpyrifos NGM, and 3mg/L Chlorpyrifos NGM, all seeded with OP50 E. coli as 
a food source. Populations of C. elegans were left on treatment or control media for 48 hours, 
allowing the control group to mature to the L4/Young Adult stage before egg laying had begun. 
At this point, worms were transferred to fresh treatment media of the type on which worm 
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populations were raised with fresh OP50 E. coli. After a two-hour acclimation period, 30 second 
videos of individual worms were recorded. For each video, pharyngeal pump rate for the 
recorded worms was determined by counting the total number of pumps and dividing this by the 
length of the video in seconds. 
Apoptosis Assay 
 Apoptosis assays were done utilizing the MD701 C. elegans strain. Apoptotic germ cells 
are visualized through a CED-1::GFP fusion protein that marks somatic cells clustering around 
the apoptotic cells during engulfment.52 Samples of adult worms were taken after the previously 
outlined exposure period, suspended on agarose on slides, and paralyzed with a 5mM solution of 
Levamisole. 
 Once suspended on slides, 40 to 50 worm gonads per treatment were examined utilizing 
fluorescent microscopy. GFP positive cells within the gonad were quantified, with particular 
interest paid to apoptotic cells residing within the gonad loop. Average numbers of apoptotic 
cells per treatment group were taken and compared. 
Dopaminergic Neuron Assessment 
 Synchronized UA44-strain C. elegans were plated as outlined in the exposure period 
procedure. Worm populations were allowed to grow on treatment or control media for 48 hours, 
leaving the majority of worms in the L4/Young Adult life stage. At this point, C. elegans 
populations were washed and transferred onto fresh non-treatment NGM seeded with OP50 E. 
coli, where they were allowed to grow for at least 24 hours. At this point, worms were fully 
mature adults, producing observable eggs. 
 Exposed and control worms were then mounted onto slides and paralyzed with exposure 
to 5mM Levamisole solution. For each treatment, 100 individual worms were observed with a 
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GFP fluorescent microscope, specifically examining the head dopaminergic neurons. These 
neurons are the set of four CEP neurons and the pair of ADE neurons. Counts of fluorescent 
neurons were taken for each individual worm and differences between these counts among 
























Impact of Chlorpyrifos Treatment on Worm Body Size 
 Analysis of videos through Wormlab shows nonsignificant changes between the control 
and low dose treatment groups among all tested parameters. At low doses of environmental 
chlorpyrifos, worms showed a small increase in both length and width that was not significant at 
the 95% confidence level. C. elegans grown for 48 hours on 1ug/L Chlorpyrifos Nematode 
Growth Media showed an average body size slightly above the control group, with greater length 
(840.69±6.69μm) and greater width (102.8±2.2μm). In comparison, control C. elegans that 
weren’t exposed to chlorpyrifos had an average body length of 813.4±9.5μm and an average 
body width of 98.44±1.77μm. Worm area, as a derivative endpoint of length and width, was 
likewise higher among the low dose group than among the control. An average low dose group 
worm had a body area of 87915.9±2057.8μm2 while a control worm had an average body area of 
81452.21±1809.01μm2. The difference in body size is small, roughly a 3% increase in length a 
4% increase in width, and an 8% increase in body area; future testing would be necessary to 
determine if such an increase is significant or due to treatment.  
Worms exposed to chlorpyrifos at the 3mg/L level during development did show 
significant (P<0.05) decreases in body size when compared either to control groups or low dose 
groups. Worm bodies were shorter (601.23±14.18μm), thinner (86.01±2.21μm), and overall 
smaller in total area covered (53033.89±2389.87μm). It is theorized that these decreases in body 
size were at least partially attributable to starvation during development, along with some 
developmental delay within heavily exposed worms. Results of body length and width analysis 




Impact of Chlorpyrifos Treatment on Body Wavelength and Amplitude 
 When corrected for body size, differences in wavelength were minor and statistically 
indistinguishable among treatment groups. Control group worms had an average wavelength to 
body length ratio of 0.515±0.007, low dose worms had a ratio of 0.504±0.009, and high dose 
worms had a ratio 0.508±0.011. Differences within the amplitude to body length ratios among 
groups were likewise statistically indistinguishable. The average ratio was 0.0488±0.0029 among 
the control group, 0.04955±0.0051 within the low dose group, and 0.0502±0.0050 among the 
high dose group. Based on this data, it seems unlikely that developmental exposure to 
chlorpyrifos influences worm body posture in adulthood. Results for wavelength and amplitude 
are shown in fig.6 and fig.7. Results are listed in table 2. 
Impact of Chlorpyrifos Treatment on Movement Speed 
 As with body size, lightly exposed worms showed non-significant increases in speed 
over the control group. An average control worm had a forward speed of 28.08±4.59μm/s and an 
average reverse speed of 31.48±5.05μm/s. Worms exposed to low levels of chlorpyrifos during 
development had an average forward speed of 36.87±4.77μm/s and an average reverse speed of 
40.32±6.91μm/s. On average, low dose worms were roughly 31% faster than control worms 
moving forward and 28% faster moving in reverse. The differences in speed shown between the 
control and low group was more drastic than other measured endpoints and the observed increase 
in movement speed goes opposite of expectations. Assuming future studies on movement speed 
show significance, it is possible that chlorpyrifos may be acting as a stimulant at very low 
concentrations.  
Heavily exposed worms responded to developmental treatment as expected, with 
decreases in both forward and reverse movement speeds compared both to control and low dose 
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worms. An average high dose worm had a forward speed of 18.92±2.72μm/s and a reverse speed 
of 19.57±3.02μm/s. The observed difference between control and high dose worms was not 
significant at the p<0.05 level, though there was significance (p<0.05) when comparing the high 
dose and low dose groups. All groups showed greater reverse speeds than forward speeds. 
Results are shown in fig. 8 and measurements are listed in table 3. 
Impact of Chlorpyrifos Treatment on Reversal Ratios 
 Except for a significant (p<0.05) difference between high and low dose worms, there was 
no determinable difference in reversal ratios between the three groups. Disregarding 
significance, C. elegans exposed to low doses of chlorpyrifos during development had the lowest 
reversal ratios, spending 22% of recorded time moving in reverse. The control group had the 
second highest reversal ratio, with 27% of recorded time spent moving backwards. Finally, the 
heavily exposed group spent the greatest amount of time in reversal, with 34% of recorded time 
spent moving in reverse. With the only statistically distinguishable difference between groups 
being between the low and high dose treatment groups, it’s difficult to draw conclusions from 
these results. However, it is possible that high dose worms are more sensitive to adverse stimuli 
that would trigger a reversal response. Conversely, low dose worms may lose a degree of this 
sensitivity. Results are shown in fig. 9 and listed in table 3. 
Chlorpyrifos Exposure Induced Germline Apoptosis 
 Looking specifically at numbers of apoptotic germ cells within the gonad loop, control 
and low dose chlorpyrifos groups showed comparable levels of apoptotic cells, with the low dose 
group showing an observable but not significant increase compared to control. An average 
control gonad contained 0.77±0.11 observed apoptotic cells, while the gonad of a worm exposed 
to 1μg/L chlorpyrifos during development contained 1.25±0.19 apoptotic cells. There is an 
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increase observed between the two groups, though the difference between the two groups doesn’t 
meet a p<0.05 significance threshold. Further testing with a greater number of worm gonads may 
show a statistically supportable difference that potentially indicates stress beyond that which is 
caused by bodily paralysis. The degree of difference between the two groups is substantial, if not 
statistically significant, indicating an increase in the occurrence of apoptosis by 60% over control 
with just mild exposure to chlorpyrifos. 
 C. elegans exposed to high doses of chlorpyrifos showed a notable and significant 
(p<0.05) increase in the number of apoptotic loop germline cells, with a 64% increase in 
apoptotic cells compared to the low dose group and a 166% increase in apoptotic cells compared 
to control groups. An average worm exposed to 3mg/L chlorpyrifos during development showed 
2.05±0.21 observed apoptotic cells per gonad. As of yet, it is unclear if this increase is due to 
direct stress caused by chlorpyrifos or an indirect result due to physical impairment during larval 
stages. Representative images of germlines are shown in fig.10. Apoptotic cell counts are shown 
in fig.11 and counts are recorded in table 4. 
Chlorpyrifos Exposure induced aberrant Pharyngeal Pumping 
 As with other experiments utilizing the N2-strain of C. elegans, the pharyngeal pumping 
assay attempted did not indicate any significant differences between the control treatment group 
and the 1ug/L Chlorpyrifos treatment group. Both groups showed pumping rates slightly above 
2.5 pumps per second. Specifically, the control group showed a rate of 2.66±0.06pumps/sec, just 
slightly above the 2.59±0.06pumps/sec rate for worms exposed to 1μg/L chlorpyrifos. 
Differences in pharyngeal pumping were nigh indistinguishable between the two groups, and it 




The 3mg/L Chlorpyrifos treatment group however, showed a significant decrease 
(p<0.001) when compared to the other two groups. The average pharyngeal pumping rate of a 
worm under heavy chlorpyrifos exposure was 1.697±0.062pumps/sec. This represents a roughly 
36% drop compared to the control pumping rate. This suggests chlorpyrifos, at higher doses, has 
the expected paralytic effect on C. elegans. Assuming that this paralysis is inhibiting food 
consumption, it is possible that the impact chlorpyrifos has on worm body size and development 
may be partially due to induced starvation. Results are shown in fig.12 and recorded in table 5.  
Chlorpyrifos Exposure induced aberrance in Dopaminergic Neurons 
 Both the 1ug/L Chlorpyrifos treatment group and 3mg/L Chlorpyrifos treatment group 
showed a significant (p<0.05) increase in the proportion of showing damage or degradation to 
dopaminergic neurons, as measured by loss of GFP visibility. This is significant within low dose 
groups, given previous experiments’ inability to assess any differences between control worms 
and lightly exposed worms. 
 The ratio of control worms showing any signs of dopaminergic neuron degradation was 
0.10±0.03. One in ten worms examined showed loss of GFP in one or more neurons. Among 
worms exposed to 1μg/L chlorpyrifos during development, the ratio of worms showing GFP loss 
within neurons was 0.25±0.04, meaning one in four worms showed neural degradation. This 
ratio was similar within heavily exposed worm populations; a ratio of 0.26±0.04 for GFP loss 
was observed among the 3mg/L chlorpyrifos treatment group. There was no statistically 
distinguishable difference between the ratios of GFP loss among the low and high treatment 
groups. 
Breaking down GFP loss by neuron type, ADE neurons show more dramatic differences 
among groups. The control group had GFP loss within ADE neurons in only 4±2% of 
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individuals. The percentage of ADE-GFP loss among the low dose treatment group was 11±3% 
and was 14±4% among the high dose group. While differences in damaged proportion could not 
be statistically distinguished between the 1ug/L Chlorpyrifos exposed group and either the 
control or 3mg/L treatment group, the 3mg/L treatment group showed a significant difference 
(p<0.05) in proportion showing ADE damage when compared against the control.  
The percentage of the control group with CEP neuron degradation was 8±3%. Among the 
low and high treatment groups, this percentage was elevated to 17±4% and 14±4% respectively. 
Damage to CEP neurons seems elevated among the two treatment groups, but the observed 
differences cannot be statistically distinguished from control and damage does not seem to 
increase with increasing dose. 
Images of C. elegans dopaminergic neurons post treatment are shown in fig.13. Results of 
Dopaminergic Neuron Assay are presented in fig.14 and fig.15. Results of assays are listed in 
table 6. 
Statistical Analysis 
 Statistical significance among body size measurements, posture/coordination 
measurements, movement speeds, reversal ratios, apoptotic cell counts, and pharyngeal pumping 
rates was assessed by way of one-way ANOVA analysis, utilizing a Bonferroni Correction post-
hoc test for comparisons between groups. To determine significant differences in proportions of 
worms showing GFP loss in dopaminergic neurons among different treatments, a chi-square test 
was utilized at the 0.05 significance level with a post-hoc Bonferroni Correction. 










 Among all bodily measurements, C. elegans exposed to low levels of chlorpyrifos during 
development showed no significant difference from control worms at the adult stage, though 
there was a nonsignificant increase in length and width. From this, along with data from other 
experiments, it is possible to conclude that chlorpyrifos at the 1ug/L level does not have a strong 
toxicological impact on C. elegans when excluding impacts on the nervous system. The chemical 
at this level does not appear to cause overwhelming bodily stress to the point where development 
is impacted. However, further experiments may need to be done to see if any delayed effects can 
be observed later in the C. elegans lifespan. 
 In contrast to low dose chlorpyrifos treatment, the 3mg/L chlorpyrifos treatment led to an 
observed developmental delay and decrease in body size. The developmental delay is consistent 
with previous reports on the effects of chlorpyrifos exposure on C. elegans.24 However, the 
decrease in body size seems to go beyond a simple developmental delay during video recording 
and extend to a genuine decrease in adult body size, an indicator of stress. Without further 
experimentation, the exact cause of this decrease is unknown, though other performed trials 
indicate starvation due to paralysis may be a possible contributing factor. 
 Of note, significant changes in morphology seem limited to a decrease in body size 
among heavily exposed C. elegans. Body wavelength and amplitude are comparable to control 
and low dose treatment groups. These two measurements can be thought of as partially 
analogous to coordination, or how C. elegans tend to propagate their bodies along a substrate. 
The similarity among the groups indicates no lingering paralysis within muscles in the heavily 
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exposed group, indicating that any lingering chlorpyrifos exposure was minimal to nonexistent 
once exposed worms were transferred to non-treatment agar. 
Mobility Impact 
 The lasting impact of chlorpyrifos on wild-type C. elegans mobility seems difficult to 
distinguish. Except for the differences in forward and reverse speeds observed between the low 
and high dose treatment groups, no significant difference in speed could be observed. Looking at 
the whole of the data, changes in speed do not follow an expected trend line, with speed 
decreasing slightly under low doses and decreasing noticeably at high exposure. Rather speed 
seems to increase slightly with light exposure during development and then decrease with heavy 
exposure. At low doses, chlorpyrifos does not seem to induce a Parkinson-like phenotype at the 
chosen time point, with exposed worms showing no evidence of movement impairment.  
 In the very least, the results obtained may be indicative of differing effects of 
chlorpyrifos, and potentially different toxicologies, when exposure occurs at different doses. The 
observed nonsignificant movement increase is perhaps too great to fully disregard and may need 
further trials to determine if changes are truly significant. What would cause such an increase in 
speed also requires investigation. It is known that CEP and ADE neurons within C. elegans help 
to produce a basal slowing response when food is present. Damage in these neurons could 
potentially produce a worm that doesn’t readily slow its movement on food sources, which could 
explain the observed increases. 
 As of now however, it cannot be said that developmental exposure to chlorpyrifos at the 
1μg/L concentration has any effect on adult C. elegans movement speed. There is some evidence 
that heavier exposure, at the 3mg/L concentration, could have a lasting impact on movement 
29 
 
speed. However, without significant difference from an unexposed control group, this cannot be 
stated definitively. 
Chlorpyrifos as a Stressor 
 At high concentrations, chlorpyrifos seems to possess the ability, either directly or 
indirectly, to increase apoptosis within C. elegans germline cells. Worms exposed to high doses 
of the compound during development, high enough doses to cause developmental delays and 
smaller adult sizes, showed apoptotic cell counts over twice that of unexposed MD701-strain 
worms. While it wasn’t assessed in current experiments, this might indicate an impact on later 
reproductive success within exposed worms along with multigenerational toxic effects. A portion 
of this increase in apoptotic cell count might be attributable to partial paralysis during 
development, resulting in the observed decrease in pharyngeal pumping rate among heavily 
exposed worms. This decrease could inhibit a worm’s ability to feed, causing starvation which is 
a known cause of increased germline cell apoptosis.23   
 Though low doses of chlorpyrifos (1μg/L) during development did not produce 
significant increases in apoptotic cell count over unexposed worms, there was a nonsignificant 
increase which may deserve further investigation. As expected, the average number of apoptotic 
cells per worm gonad seems to fall along a trend line, with increasing numbers occurring with 
increasing dose. If this increase is supported in later studies, this might indicate action of 
chlorpyrifos as a cellular stressor beyond nutrient deprivation via muscle paralysis. At this 
concentration, chlorpyrifos does not seem to significantly inhibit acetylcholinesterase but may 




Effects on Dopaminergic Neurons 
Initial results seem to indicate that chlorpyrifos, whether directly or indirectly, is causing 
some degree of damage to dopaminergic neurons. Given previous results showing that high 
exposure to chlorpyrifos caused significant bodily stress within worms, at least partially these 
results are not particularly surprising. Within high dose groups, a portion of neuron degradation 
might be attributable to poor nutrition and starvation, in addition to any direct stress the 
compound may have had upon the cells. 
 What is more surprising however, is the degree to which C. elegans exposed to a low 
dose of chlorpyrifos showed dopaminergic neuron loss. The experiment showed a rate of 
abnormality significantly greater than unexposed worms and statistically indistinguishable from 
worms receiving a high dose. This is particularly startling since C. elegans in previous 
experiments did not show either significant signs of stress or impairment at this chemical dose. It 
should be noted that behavioral studies were not performed with the transgenic UA44 strain, 
which may show greater morphological impairment or locomotion alterations with 
developmental chemical exposure. 
 As of yet, it is unknown how chlorpyrifos might be impacting dopaminergic neurons 
within C. elegans. The compound can be considered either a direct cause or an enhancer, which 
may exacerbate the disease progression to a point in which it is notable. Since UA44-strain of C. 
elegans experiences age-related dopamine neuron degradation due to α-synuclein expression, the 
latter explanation may be considered more probable at this point.53 Further studies will need to 






 The vast majority of research detailed above focused on endpoints found within a very 
narrow age range. Observed C. elegans were usually adults right at the onset of egg-laying. It’s 
possible that developmental exposure could cause damage observable at later life stages and 
might potentially accelerate age-related deterioration. This is of particular interest in the study of 
Parkinson’s Disease, which tends to emerge later in life. Behavioral observations of older worms 
might produce more pronounced differences between treatment groups than did observation of 
younger worms. Conversely, it is possible that some of the morphological changes observed in 
heavily exposed C. elegans (shorter body length and narrower width) might dissipate with age; 
worms could continue to grow over their lifespan and differences between the treatment groups 
might vanish. 
Concentration Variances 
 These studies were limited to two distinct and separate chlorpyrifos doses: a low dose 
(1μg/L) which was hypothesized to have limited effect and cause little disruption of 
acetylcholinesterase, and a high dose (3mg/L) that would follow expected toxicological 
mechanisms for chlorpyrifos. In this dose selecting, middling concentrations were ignored. 
Seeing C. elegans reactions to a wider variety of doses might help establish trend lines among 
measured endpoints and better characterize the exact reactions of the organism to the compound. 
This will be especially pertinent if future research finds significant differences in C. elegans 
locomotion and morphology between no exposure and 1μg/L developmental chlorpyrifos groups. 
Assuming such research agrees with the data presented above, which showed nonsignificant 
increases in locomotion and body size among the low exposure group, a greater number of 
concentration treatments both below and above the low exposure group will be necessary to 
determine the presence of a potential hormetic effect. 
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Determining Apoptotic Action 
 While developmental chlorpyrifos exposure has seemingly increased the incidence of C. 
elegans apoptotic germline cells during adulthood, it is unknown by what mechanism it causes 
this phenomenon. Fortunately there are several proteins known within C. elegans apoptotic 
pathways that can be examined for their role in chlorpyrifos-triggered apoptosis. For example, it 
is known that oxidative, osmotic, and heat stress induced apoptosis in C. elegans depend on the 
MAPK kinases MEK-1 and SEK-1 along with ABL-1.54 Observing the effects of chlorpyrifos in 
absence of any one of these proteins would help elucidate the exact contribution of starvation 
towards germline apoptosis in previously mentioned experiments. It would also potentially 
implicate chlorpyrifos as an oxidative stressor. Though chlorpyrifos is not a known genotoxin, 
further experiments could also be performed on C. elegans that lack CEP-1, which is required for 
DNA damage induced germline apoptosis.55 No change in rates of germline apoptosis would 
further specify the action of the compound; a decrease in apoptosis however might indicate 
previously unaddressed toxicological facets of chlorpyrifos. 
Elucidating Effects on Dopaminergic Neurons 
 The above experiments indicated the potential for developmental chlorpyrifos exposure 
to directly cause or enhance dopaminergic neuron degeneration, but there are still several 
questions to be answered. The UA44 strain of C. elegans is partially humanized due to 
production of human α-synuclein, allowing its dopaminergic neurons to function as a better 
simulacrum for human dopaminergic neurons. With the addition of α-synuclein, C. elegans 
possesses all major proteins whose dysfunction is associated with Parkinson’s Disease. However, 
as a result of α-synuclein expression, C. elegans naturally experiences dopaminergic neuron loss 
over its lifespan. An important question is whether an increase in neuron loss would occur in 
33 
 
absence of α-synuclein, or are the observed negative effects of chlorpyrifos dependent on action 
upon α-synuclein. To this end, similar trials should be performed on other strains of C. elegans, 
possibly with dopaminergic neurons visualized in a different manner. It has also yet to be 
confirmed that UA44-strain C. elegans has the same vulnerability to chlorpyrifos that wild-type 
C. elegans possesses. Behavioral studies with WormLab on the UA44-strain could provide 
evidence that the two react similarly to the compound. Alternatively, signs of poor coordination 
like slower movement or irregular body wavelength or motions could be related to the symptoms 
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VII. Tables and Figures 
 
Endpoint Treatment N Mean (µm) Std. Deviation Std. Error 
Length DMSO-Control 30 813.40 52.03 9.50 
1ug/L Chlorpyrifos 25 840.69 33.47 6.69 
3mg/L Chlorpyrifos 23 601.23 68.00 14.18 
Width DMSO-Control 30 98.44 9.68 1.77 
1ug/L Chlorpyrifos 25 102.80 11.07 2.21 
3mg/L Chlorpyrifos 23 86.01 10.58 2.21 
Area DMSO-Control 30 81452.21 9908.33 1809.01 
1ug/L Chlorpyrifos 25 87915.86 10289.00 2057.80 
3mg/L Chlorpyrifos 23 53033.89 11461.44 2389.87 
























Endpoint Treatment N Mean Std. Deviation Std. Error 
Wavelength:Body 
Length Ratio 
DMSO-Control 30 0.5150692 0.03682317 0.006723 
1ug/L Chlorpyrifos 25 0.5035531 0.04636112 0.009272 
3mg/L Chlorpyrifos 23 0.5079139 0.05385663 0.01123 
Amplitude:Body 
Length Ratio 
DMSO-Control 30 0.0487664 0.01576667 0.002879 
1ug/L Chlorpyrifos 25 0.0495531 0.02565579 0.005131 
3mg/L Chlorpyrifos 23 0.0502066 0.02402462 0.005009 


























Endpoint Treatment N Mean Std. Deviation Std. Error 
Forward 
Speed 
DMSO-Control 28 28.0753 µm/s 24.28366 4.58918 
1ug/L Chlorpyrifos 24 36.8651 µm/s 23.38231 4.77289 
3mg/L Chlorpyrifos 23 18.924 µm/s 13.0344 2.71786 
Reverse Speed DMSO-Control 28 -31.4809 µm/s 26.74447 5.05423 
1ug/L Chlorpyrifos 24 -40.317 µm/s 33.8729 6.91428 
3mg/L Chlorpyrifos 23 -19.5694 µm/s 14.50439 3.02437 
Reversal Ratio DMSO-Control 28 0.2718 0.1011 0.01911 
1ug/L Chlorpyrifos 24 0.2167 0.13526 0.02761 
3mg/L Chlorpyrifos 23 0.3358 0.11609 0.02421 


























Treatment Group N Mean Apoptotic Cells Std. Error 
DMSO Control 61 0.7705 0.11062 
1ug/L Chlorpyrifos 60 1.25 0.1881 
3mg/L Chlorpyrifos 60 2.05 0.21448 





























Treatment N Pumps/sec Std. Error 
DMSO Control 25 2.6638 0.06191 
1ug/L Chlorpyrifos 20 2.5882 0.06322 
3mg/L Chlorpyrifos 20 1.6975 0.0619 


































Control 100 0.1±0.030 0.04±0.020 0.08±0.027 
1ug/L Chlorpyrifos 100 0.25±0.043 0.11±0.031 0.17±0.038 
3mg/L Chlorpyrifos 100 0.26±0.044 0.14±0.035 0.14±0.035 




















































Fig 2. Overview of C. elegans treatment timeline Organisms to be synchronized to produce an initial population 
consisting entirely of L1 larvae. Organisms are exposed to chlorpyrifos through larval stages up to young adulthood 








































   
Fig 4. C. elegans gonad overview, taken from Gumienny et al. 1999 .58 All GFP positive cells along gonad are 














Fig 5. Average C. elegans length and width among low and high chlorpyrifos treatment groups. Hermaphroditic 
worms exposed for 48 hours from larval stage 1 to stage 4. Videos taken of young adult worms 9 to 11 hours after 
treatment. High treatment group experienced developmental delay during treatment. Measurements from WormLab 

















































Fig 6.  Average corrected wavelength (wavelength/body length) of C. elegans body after developmental 
chlorpyrifos treatment. Worms exposed for 48 hours from larval stage 1 to stage 4. Videos taken of young adult 




































Fig 7.  Average corrected amplitude (amplitude/body length) of C. elegans body after developmental chlorpyrifos 
treatment. Worms exposed for 48 hours from larval stage 1 to stage 4. Videos taken of young adult worms 9 to 11 
hours after treatment. Measurements from WormLab analysis of videos. Mean amplitude of a single organism an 









































Fig 8. Average C. elegans forward and reverse speed among low and high chlorpyrifos treatment groups. Worms 
exposed for 48 hours from larval stage 1 to stage 4. Videos taken of young adult worms 9 to 11 hours after 






























C. Elegans Movement Speed




Fig 9. Average portion of time spent in reversal for low and high treatment groups. Ratio calculated by taking 
number of frames in video where worms were in reversal and dividing by total number of frames for the video. 















































Fig 10. Images of MD701-strain C. elegans germlines after exposure to chlorpyrifos during development. Line 
indicates demarcation of gonadal loop, wherein apoptotic cells were counted. Rings of GFP fluorescence identify 
apoptotic cells undergoing engulfment, identified by white arrows. Heavily exposed worms showed an increase in 






















Fig 11. Observed number of apoptotic germline cells in MD701 strain C. elegans after 48 hours chlorpyrifos 
exposure and 1 day free of exposure. Adult, egg-laying worms were examined and apoptotic cells within the gonad 














































Pharyngeal Pumping Assay 
 
Fig 12. Pharyngeal pumping rates of C. elegans exposed to low dose and high dose chlorpyrifos treatments. Videos 
were taken of 20-25 worms per treatment group and the average pumping rate for the group was calculated by 
counting the number of pharyngeal movements and dividing by video time. Young adult worms recorded on 


































C. elegans Pharyngeal Pumping Rate
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Dopaminergic Neuron Assay 
 
Fig 13. Images of Head Dopaminergic Neurons in UA44 C. elegans exposed to chlorpyrifos during development. 
White arrows identify CEP neurons (4 present in DMSO-Control, 2 in both 1μg/L and 3mg/L Chlorpyrifos exposed 
individuals) and red arrows identify ADE neurons (2 present in all individuals). Treatment groups showed loss of 























Fig 14. Proportion of UA44-strain C. elegans displaying loss of GFP in head dopaminergic neurons after 48hr 
exposure to Chlorpyrifos and 1 day free of exposure. Per group, 100 organisms were examined. An organism was 
considered positive for GFP loss if one or more of its two ADE neurons or four CEP neurons could not be found. * 











































Fig 15. Breakdown of GFP loss within UA44-strain C. elegans dopaminergic neurons by neuron type. Shown is the 
proportion of each treatment group showing loss of GFP in either ADE or CEP neurons. * indicates significant 
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